Swedish biotech Sobi has announced positive results from the AVA-PED-301 study, evaluating the efficacy and safety of Doptelet (avatrombopag). 25 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.